|Daily Range||$35.09 - $35.47|
|52-Week Range||$32.08 - $38.54|
|Dividend (Yield)||$0.00 (2.3%)|
|Average Daily Volume||1,699,855|
|Current FY EPS||$1.88|
News & Commentary
Exelixis Inc.'s FDA review for approval of cobimetinib has been delayed until November.
A detailed step-by-step guide on how a drug goes from a concept in the lab to a product on pharmacy shelves, and how the drug development process can affect your investments.
The biotech sector has already had an incredible run, but these two stocks look as if their momentum could continue for years to come.
Cancer immunotherapy is rapidly becoming a major new weapon in the fight against this deadly disease. Here is a brief primer on this powerful new technology, as well as a look at where it's likely headed moving forward.
Nearly 90% of biotech stocks are losing money, but that doesn't mean our healthcare analysts don't perceive there to be value in the sector.
A closer look at gene sequencing stocks -- and how you could score a double helix of gains
Could Roche, iRobot, and IBM represent the future of healthcare?
Celldex Therapeutics reported some highly encouraging data for its experimental brain cancer vaccine Rintega at the recent ASCO meeting. Could this vaccine prove to be a game-changer in the fight against this deadly disease?
Shares of the struggling biopharma ImmunoGen skyrocketed today following a clinical update at the American Society of Clinical Oncology meeting. Here's what you need to know moving forward.
Biotech has produced numerous stocks recently that have doubled or tripled in short periods of time. Here is a look at three small-cap companies with the potential to continue this trend.